Home > Research > Publications & Outputs > Acylated Ghrelin as a Multi-Targeted Therapy fo...


Text available via DOI:

View graph of relations

Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Article number614828
<mark>Journal publication date</mark>14/12/2020
<mark>Journal</mark>Frontiers in Neuroscience
Number of pages35
Publication StatusPublished
<mark>Original language</mark>English


Much thought has been given to the impact of Amyloid Beta, Tau and Alpha-Synuclein in the development of Alzheimer's disease (AD) and Parkinson's disease (PD), yet the clinical failures of the recent decades indicate that there are further pathological mechanisms at work. Indeed, besides amyloids, AD and PD are characterized by the culminative interplay of oxidative stress, mitochondrial dysfunction and hyperfission, defective autophagy and mitophagy, systemic inflammation, BBB and vascular damage, demyelination, cerebral insulin resistance, the loss of dopamine production in PD, impaired neurogenesis and, of course, widespread axonal, synaptic and neuronal degeneration that leads to cognitive and motor impediments. Interestingly, the acylated form of the hormone ghrelin has shown the potential to ameliorate the latter pathologic changes, although some studies indicate a few complications that need to be considered in the long-term administration of the hormone. As such, this review will illustrate the wide-ranging neuroprotective properties of acylated ghrelin and critically evaluate the hormone's therapeutic benefits for the treatment of AD and PD.